Next week: AI's moment of truth

Tuesday, October 14, 2025 | Georgia Room, NYC | Hybrid

Wall Street's AI jitters are impossible to ignore. As questions swirl about whether the broader AI boom is headed for a correction, biopharma finds itself facing its own moment of truth.

Join us for a hybrid deep dive into what's real and what's overvalued: a full morning of virtual sessions, followed by an exclusive in-person evening in New York City with live editorial conversations and networking over food & drinks at NYC’s Georgia Room.

JOIN US

Led by award-winning senior biopharma correspondent Andrew Dunn, we'll unpack how the industry has poured billions into AI with promises of slashing development timelines and R&D costs. Can these investments withstand economic turbulence and deliver actual breakthroughs?

Georgia Room, NYC

Join us for conversations with...

Morning sessions (virtual)

Max Jaderberg, chief AI officer, Isomorphic Labs
Miles Congreve, CSO, Isomorphic Labs
Vivek Natarajan, research scientist, Google DeepMind — who co-led development on Google’s AI co-scientist project earlier this year

While Big Pharma doubles down and startups bet everything on AI-first approaches, the pressure is mounting to show results. Join us.

REGISTER NOW